Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amrubicin + Cisplatin vs Etoposide + Cisplatin in ED-SCLC
NCT00660504Phase 3Completed
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2008
- Primary completion
- Feb 2012
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of amrubicin in small cell lung cancer (SCLC), sponsored by Sumitomo Pharma. Started Apr 2008; status: completed.
02
Drugs
amrubicin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00660504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00660504.